EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome

Objective To develop a disease activity index for patients with primary Sjögren's syndrome (SS): the European League Against Rheumatism (EULAR) Sjögren's syndrome disease activity index (ESSDAI). Methods Thirty-nine SS experts participated in an international collaboration, promoted by EULAR, to develop the ESSDAI. Experts identified 12 organ-specific ‘domains’ contributing to disease activity. For each domain, features of disease activity were classified in three or four levels according to their severity. Data abstracted from 96 patients with systemic complications of primary SS were used to generate 702 realistic vignettes for which all possible systemic complications were represented. Using the 0–10 physician global assessment (PhGA) scale, each expert scored the disease activity of five patient profiles and 20 realistic vignettes. Multiple regression modelling, with PhGA used as the dependent variable, was used to estimate the weight of each domain. Results All 12 domains were significantly associated with disease activity in the multivariate model, domain weights ranged from 1 to 6. The ESSDAI scores varied from 2 to 47 and were significantly correlated with PhGA for both real patient profiles and realistic vignettes (r=0.61 and r=0.58, respectively, p<0.001). Compared with 57 (59.4%) of the real patient profiles, 468 (66.7%) of the realistic vignettes were considered likely or very likely to be true. Conclusions The ESSDAI is a clinical index designed to measure disease activity in patients with primary SS. Once validated, such a standardised evaluation of primary SS should facilitate clinical research and be helpful as an outcome measure in clinical trials.

[1]  A. Vissink,et al.  Rituximab treatment in primary Sjogren's syndrome : A double-blind placebo controlled trial , 2008 .

[2]  J. Krischer,et al.  Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis , 2008, Annals of the rheumatic diseases.

[3]  P. Merkel,et al.  Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. , 2008, Arthritis and rheumatism.

[4]  P. Emery,et al.  Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study , 2008, Annals of the rheumatic diseases.

[5]  D A Isenberg,et al.  Sjögren's Systemic Clinical Activity Index (SCAI)--a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome. , 2007, Rheumatology.

[6]  S. Bombardieri,et al.  Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. , 2007, Arthritis and rheumatism.

[7]  B. Cochener,et al.  Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). , 2007, Arthritis and rheumatism.

[8]  X. Mariette,et al.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome , 2006, Annals of the rheumatic diseases.

[9]  L. Jacobsson,et al.  Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors , 2005, Annals of the rheumatic diseases.

[10]  A. Vissink,et al.  Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. , 2005, Arthritis and rheumatism.

[11]  X. Mariette,et al.  Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome , 2005, Annals of the rheumatic diseases.

[12]  A. Vissink,et al.  Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren’s syndrome and associated MALT lymphoma , 2004, Annals of the rheumatic diseases.

[13]  S. Pillemer,et al.  Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. , 2004, Arthritis and rheumatism.

[14]  G. Baron,et al.  Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). , 2004, Arthritis and rheumatism.

[15]  Edward C. Jones,et al.  A comparison of two time intervals for test-retest reliability of health status instruments. , 2003, Journal of clinical epidemiology.

[16]  R. Jonsson,et al.  Revisiting Sjögren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. , 2001, Rheumatology.

[17]  S. Bowman,et al.  Outcome measures in Sjögren's syndrome. , 2001, Rheumatology.

[18]  D. Altman,et al.  Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.

[19]  F. Vivino,et al.  Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. , 1999, Archives of internal medicine.

[20]  P. Venables,et al.  A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. , 1998, The Journal of rheumatology.

[21]  A. Tzioufas,et al.  Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. , 1996, Arthritis and rheumatism.

[22]  E. Schned,et al.  Derivation of the SLEDAI. , 1993, Arthritis and rheumatism.

[23]  A. van der Heide,et al.  Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. , 1993, Annals of the rheumatic diseases.

[24]  van der Heijde Dm,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993 .

[25]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[26]  D. Symmons,et al.  Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). , 1988, The Quarterly journal of medicine.

[27]  D. Symmons,et al.  Development and Assessment of a Computerized Index of Clinical Disease Activity in Systemic Lupus Erythematosus , 1988 .

[28]  V. Yohai.  HIGH BREAKDOWN-POINT AND HIGH EFFICIENCY ROBUST ESTIMATES FOR REGRESSION , 1987 .

[29]  C. Papadimitriou,et al.  Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study. , 1986, Annals of the rheumatic diseases.

[30]  P. Rousseeuw.  Least Median of Squares Regression , 1984 .

[31]  A. Claudy,et al.  Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.

[32]  Jacob Cohen,et al.  Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .

[33]  Jacob Cohen.  A Coefficient of Agreement for Nominal Scales , 1960 .

[34]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[35]  S. Pillemer,et al.  Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. , 2005, The Journal of rheumatology.

[36]  A. Vissink,et al.  Rituximab treatment in primary Sjogren's syndrome , 2005 .

[37]  M. A. van 't Hof,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993, The Journal of rheumatology.